Improving outcomes in patients at risk for venous thromboembolism following total knee and total hip replacement: implications for managed care
- PMID: 21819165
Improving outcomes in patients at risk for venous thromboembolism following total knee and total hip replacement: implications for managed care
Abstract
An estimated 1 million Americans suffer from venous thromboembolism (VTE) annually and more than 600,000 experience symptomatic VTE events each year. Patients undergoing total knee replacement (TKR) and total hip replacement (THR) are at high risk for developing VTE (40%-60% risk without prophylaxis). The economic burden of post-TKR/THR VTE is very large, with the average length of stay more than double that of patients without VTE, and risk-adjusted overall costs 4 and 5 times greater among the TKR and THR populations, respectively, compared with non-VTE patients. Efforts are underway, however, in the public and private sectors to increase the rates of appropriate VTE thromboprophylaxis. Payers are experimenting with quality measurement and improvement programs to incentivize clinical behavior toward optimizing outcomes; the role of patient education in VTE prophylaxis is also evolving. There is an excellent opportunity to reshape the current patient education approach and develop appropriate, accessible materials, but, ultimately, a multipronged effort that targets as many variables related to VTE risk as possible is necessary in order to achieve success in lowering the burden of post-TKR/THR VTE.
Similar articles
-
Risks and cost burden of venous thromboembolism and bleeding for patients undergoing total hip or knee replacement in a managed-care population.J Med Econ. 2011;14(3):324-34. doi: 10.3111/13696998.2011.578698. Epub 2011 Apr 20. J Med Econ. 2011. PMID: 21506632
-
Impact of thromboprophylaxis guidelines on clinical outcomes following total hip and total knee replacement.Thromb Res. 2012 Aug;130(2):166-72. doi: 10.1016/j.thromres.2012.01.013. Epub 2012 Feb 23. Thromb Res. 2012. PMID: 22365491 Clinical Trial.
-
Cost and outcomes associated with rivaroxaban vs enoxaparin for the prevention of postsurgical venous thromboembolism from a US payer's perspective.J Med Econ. 2011;14(6):824-34. doi: 10.3111/13696998.2011.623203. Epub 2011 Oct 24. J Med Econ. 2011. PMID: 22023098
-
Ximelagatran for the prevention of venous thromboembolism following elective hip or knee replacement surgery.Semin Vasc Med. 2005 Aug;5(3):266-75. doi: 10.1055/s-2005-916166. Semin Vasc Med. 2005. PMID: 16123914 Review.
-
Prevalence and economic burden of venous thromboembolism after total hip arthroplasty or total knee arthroplasty.Am J Manag Care. 2011 Feb;17(1 Suppl):S6-8. Am J Manag Care. 2011. PMID: 21517654 Review.
Cited by
-
Incidence, characteristics, and risk factors of venous thromboembolism in shoulder arthroplasty-a systematic review.Int Orthop. 2022 Sep;46(9):2081-2088. doi: 10.1007/s00264-022-05496-w. Epub 2022 Jun 28. Int Orthop. 2022. PMID: 35761099
-
Non-compliance with clinical guidelines increases the risk of complications after primary total hip and knee joint replacement surgery.PLoS One. 2021 Nov 18;16(11):e0260146. doi: 10.1371/journal.pone.0260146. eCollection 2021. PLoS One. 2021. PMID: 34793555 Free PMC article.
-
Risk of thromboembolism in shoulder arthroplasty: effect of implant type and traumatic indication.Clin Orthop Relat Res. 2013 May;471(5):1576-81. doi: 10.1007/s11999-013-2829-6. Epub 2013 Feb 8. Clin Orthop Relat Res. 2013. PMID: 23392993 Free PMC article.
Publication types
MeSH terms
LinkOut - more resources
Medical